Lung Ultrasound + Doppler for Collapsed Lung

Overseen by Martin Girard, MD, FRCPC

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

No Placebo Group

Trial Summary

What is the purpose of this trial?

In infectious lung consolidations, the inhibition of hypoxic pulmonary vasoconstriction (HPV) results in a higher regional acceleration time (RAcT) compared to the RAcT measured in atelectatic consolidations.

Research Team

Martin Girard, MD, FRCPC

Principal Investigator

Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria

This trial is for mechanically ventilated patients with lung issues like pneumonia or a collapsed lung, visible on chest X-rays or CT scans. It's not for those in other studies, with poor ultrasound imaging conditions (like obesity), recent antibiotic changes, right heart failure, mobility restrictions of upper body, bronchoscopy contraindications, or known high blood pressure in the lungs.

Inclusion Criteria

I am on a ventilator and have lung consolidation seen in my chest X-ray or CT scan.

Exclusion Criteria

I started antibiotics or changed them between 24 to 72 hours ago.

I have conditions like severe obesity that make ultrasound images hard to read.

I cannot move my arms or upper body well.

Treatment Details

Interventions

• Lung ultrasound and Doppler (Diagnostic Test)

Trial Overview The study tests how well lung ultrasound and pulsed-wave Doppler can identify different types of lung consolidations by comparing regional acceleration time (RAcT) values between infectious and atelectatic consolidations. Measurements are taken initially and again between days 3 to 5.

Participant Groups

Group I: Lung ultrasound and Doppler, pneumonia Experimental Treatment 1 Intervention

In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0. A bronchoalveolar lavage will also be performed on Day 0.

Group II: Lung ultrasound and Doppler, atelectasis Experimental Treatment 1 Intervention

Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials

389

Recruited

143,000+

Dr. Réjean Lapointe

Centre hospitalier de l'Université de Montréal (CHUM)

Chief Medical Officer since 2023

MD from Université de Montréal

Dr. Fabrice Brunet

Centre hospitalier de l'Université de Montréal (CHUM)

Chief Executive Officer since 2015

MD from Université de Montréal

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Collaborator

Trials

54

Recruited

124,000+